The company sells products for neuroscience, oncology, women's health and cardiovascular therapeutic areas and is active in biosimilar product development. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.
Cyborg Score Rationale
Regional pharmaceutical leader with significant R&D capabilities, established market position across 100+ countries, and strategic focus on high-value therapeutic areas (oncology, neuroscience, women's health). Strengths include biosimilar pipeline development and CDMO services. Competitive pressures from multinational pharma and patent cliff risks present challenges.
Top Insights
Largest pharmaceutical company in Central and Eastern Europe with presence in UK, Western Europe, China, North America and Latin America
Cariprazine (Reagila) atypical antipsychotic awarded Medicine of the Year 2019 by Hungarian Society for Experimental and Clinical Pharmacology
Strategic collaborations with AbbVie on neuropsychiatric disease therapeutics announced October 2024
Regional expansion with subsidiaries in Romania, Poland, and Russia for localized manufacturing
Named Competitors
Oncology and Neuroscience Therapeutics — Global pharmaceutical leader